Cited by 1,258Polyomavirus and related diseasesCancer Immunotherapy and BiomarkersNonmelanoma Skin Cancer Studies

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Open access

Nghiem, Paul T., Bhatia, Shailender, Lipson, Evan J., Kudchadkar, Ragini R., Miller, Natalie J., Annamalai, Lakshmanan, Berry, Sneha, Chartash, Elliot K., Daud, Adil, Fling, Steven P., Friedlander, Philip A., Kluger, Harriet M., Kohrt, Holbrook E., Lundgren, Lisa, Margolin, Kim, Mitchell, Alan, Olencki, Thomas, Pardoll, Drew M., Reddy, Sunil A., Shantha, Erica M., Sharfman, William H., Sharon, Elad, Shemanski, Lynn R., Shinohara, Michi M., Sunshine, Joel C., Taube, Janis M., Thompson, John A., Townson, Steven M., Yearley, Jennifer H., Topalian, Suzanne L., Cheever, Martin A.·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1603702PMC PMC4927341

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma often responds to chemotherapy, but responses are transient. Blocking the programmed death 1 (PD-1) immune inhibitory pathway is of interest, because these tumors often express PD-L1, and MCPyV-specific T cells express PD-1. METHODS: In this multicenter, phase 2, noncontrolled study, we assigned adults with advanced Merkel-cell carcinoma who had received no previous systemic therapy to receive pembrolizumab (anti-PD-1) at a dose of 2 mg per kilogram of body weight every 3 weeks. The primary end point was the objective response rate according to Response Evaluation Criteria in Solid Tumors, version 1.1. Efficacy was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing. RESULTS: A total of 26 patients received at least one dose of pembrolizumab. The objective response rate among the 25 patients with at least one evaluation during treatment was 56% (95% confidence interval [CI], 35 to 76); 4 patients had a complete response, and 10 had a partial response. With a median follow-up of 33 weeks (range, 7 to 53), relapses occurred in 2 of the 14 patients who had had a response (14%). The response duration ranged from at least 2.2 months to at least 9.7 months. The rate of progression-free survival at 6 months was 67% (95% CI, 49 to 86). A total of 17 of the 26 patients (65%) had virus-positive tumors. The response rate was 62% among patients with MCPyV-positive tumors (10 of 16 patients) and 44% among those with virus-negative tumors (4 of 9 patients). Drug-related grade 3 or 4 adverse events occurred in 15% of the patients. CONCLUSIONS: In this study, first-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56%. Responses were observed in patients with virus-positive tumors and those with virus-negative tumors. (Funded by the National Cancer Institute and Merck; ClinicalTrials.gov number, NCT02267603.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1603702

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citation
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citation
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 3

10.2307/2281868 · DOI · Paper page
Berger RL, 1996, Am Stat, 50, 314
Behr DS, 2014, Int J Clin Exp Pathol, 7, 7610

Sorted by citations

Items 101–200 of 1,000

Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis
Manohar, S., Kompotiatis, P., Thongprayoon, C., Cheungpasitporn, W., Herrmann, J., & Herrmann, S. M. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy105 · Cited by 198
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022
Gauci, M.-L., Aristei, C., Becker, J. C., Blom, A., Bataille, V. A., Dréno, B., del Mármol, V., Forsea, A., Fargnoli, M. C., Grob, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.043 · Cited by 196
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195
Tuberculosis following PD-1 blockade for cancer immunotherapy
Barber, D. L., Sakai, S., Kudchadkar, R. R., Fling, S. P., Day, T. A., Vergara, J. A., Ashkin, D., Cheng, J., Lundgren, L. M., Raabe, V., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat2702 · Cited by 195
Self-citation
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study
Paulson, K. G., Lewis, C. W., Redman, M. W., Simonson, W. T., Lisberg, A. E., Ritter, D., Morishima, C., Hutchinson, K., Mudgistratova, L., Blom, A., et al. (2016) · Cancer · doi:10.1002/cncr.30475 · Cited by 190
Self-citation
Molecular approaches for classifying endometrial carcinoma
Piulats, J. M., Guerra, E., Gil-Martín, M., Roman‐Canal, B., Gatius, S., Pamplona, R. S., Velasco, A., Vidal, A., & Matías‐Guiu, X. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.12.015 · Cited by 197
The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma
Panda, A., de Cubas, A. A., Stein, M., Riedlinger, G., Kra, J., Mayer, T., Smith, C. C., Vincent, B. G., Serody, J. S., Beckermann, K. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121522 · Cited by 181
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Wagner, M. J., Othus, M. K. D., Patel, S. P., Ryan, C., Sangal, A., Powers, B., Budd, G. T., Victor, A. I., Hsueh, C.-T., Chugh, R. K., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002990 · Cited by 181
Self-citation
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Giraldo, N. A., Nguyen, P. L., Engle, E. L., Kaunitz, G. J., Cottrell, T. R., Berry, S., Green, B., Soni, A., Cuda, J. D., Stein, J. E., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0404-0 · Cited by 175
Self-citation
Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy
Yuan, H., Jiang, W., Roemeling, C. A. V., Qie, Y., Liu, X., Chen, Y., Wang, Y., Wharen, R. E., Yun, K., Bu, G., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.69 · Cited by 173
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 176
Diagnosis and Treatment of Kaposi Sarcoma
Schneider, J. W., & Dittmer, D. P. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0270-4 · Cited by 170
Microbiota dysbiosis in select human cancers: Evidence of association and causality
Chen, J., Domingue, J. C., & Sears, C. L. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.001 · Cited by 172
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Knepper, T. C., Montesion, M., Russell, J. S., Sokol, E. S., Frampton, G. M., Miller, V. A., Albacker, L. A., McLeod, H. L., Eroglu, Z., Khushalani, N. I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4159 · Cited by 172
Advances in Cancer Immunotherapy in Solid Tumors
Menon, S. P., Shin, S. J., & Dy, G. K. (2016) · Cancers · doi:10.3390/cancers8120106 · Cited by 170
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
Jelinic, P., Ricca, J. M., Oudenhove, E. V., Olvera, N., Merghoub, T., Levine, D. A., & Zamarin, D. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx277 · Cited by 171
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
Choucair, K., Morand, S. M., Stanbery, L., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 170
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Biology, evolution, and medical importance of polyomaviruses: An update
Moens, U. L., Krumbholz, A., Ehlers, B., Zell, R., Johne, R., Calvignac‐Spencer, S., & Lauber, C. (2017) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2017.06.011 · Cited by 161
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 161
Correlations between microsatellite instability and the biological behaviour of tumours
Yang, G. Y., Zheng, R.-Y., & Jin, Z. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03053-4 · Cited by 159
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
Khunger, M., Hernández, A. V., Pasupuleti, V., Rakshit, S., Pennell, N. A., Stevenson, J. P., Mukhopadhyay, S., Schalper, K. A., & Velcheti, V. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00030 · Cited by 158
Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma
Nghiem, P., Kaufman, H. L., Bharmal, M. F., Mahnke, L. A., Phatak, H. M., & Becker, J. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0072 · Cited by 156
Self-citation
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
Falchook, G. S., Leidner, R. S., Stankevich, E., Piening, B., Bifulco, C. B., Lowy, I., & Fury, M. G. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0176-3 · Cited by 152
Reconstruction of cell spatial organization from single-cell RNA sequencing data based on ligand-receptor mediated self-assembly
Ren, X., Zhong, G., Zhang, Q., Zhang, L., Sun, Y., & Zhang, Z. (2020) · Cell Research · doi:10.1038/s41422-020-0353-2 · Cited by 152
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., DAUD, A. I., Kluger, H. M., Reddy, S. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002478 · Cited by 148
Self-citation
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial
Kim, S., Wuthrick, E. J., Blakaj, D. M., Eroglu, Z., Verschraegen, C. F., Thapa, R., Mills, M. N., Dibs, K. N., Liveringhouse, C. L., Russell, J. S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01659-2 · Cited by 151
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
Lipson, E. J., Lilo, M. T., Ogurtsova, A., Esandrio, J., Xu, H., Brothers, P., Schollenberger, M. D., Sharfman, W. H., & Taube, J. M. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0228-3 · Cited by 147
Self-citation
Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma
Ritter, C., Fan, K., Paschen, A., Hadrup, S. R., Ferrone, S., Nghiem, P., Ugurel, S., Schrama, D., & Becker, J. C. (2017) · Scientific Reports · doi:10.1038/s41598-017-02608-0 · Cited by 147
Self-citation
Not All Immune Checkpoints Are Created Equal
Linhares, A. D. S., Leitner, J. M., Grabmeier‐Pfistershammer, K., & Steinberger, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01909 · Cited by 157
Immune Checkpoint in Glioblastoma: Promising and Challenging
Huang, J., Liu, F., Liu, Z., Tang, H., Wu, H., Gong, Q.-N., & Chen, J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00242 · Cited by 153
Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Niu, M., Liu, Y., Yi, M., Jiao, D., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827921 · Cited by 147
Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches
Gupta, R. G., Li, F., Roszik, J., & Lizee, G. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1575 · Cited by 144
Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Bhatia, S., Miller, N. J., Lu, H., Longino, N. V., Ibrani, D., Shinohara, M. M., Byrd, D. R., Parvathaneni, U., Kulikauskas, R. M., ter Meulen, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0469 · Cited by 141
Self-citation
Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer
Yamashita, H., Nakayama, K., Ishikawa, M., Nakamura, K., Ishibashi, T., Sanuki, K., Ono, R., Sasamori, H., Minamoto, T., Iida, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23790 · Cited by 138
A Believer’s Overview of Cancer Immunosurveillance and Immunotherapy
Finn, O. J. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701302 · Cited by 142
Reinvigorating exhausted CD8 + cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 138
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival
Melief, C. J. M., Welters, M. J. P., Vergote, I., Kroep, J. R., Kenter, G. G., Ottevanger, P. B., Tjalma, W. A. A., Denys, H., van Poelgeest, M. I. E., Nijman, H. W., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8235 · Cited by 134
The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy
Wong, A. N. M., McArthur, G. A., Hofman, M. S., & Hicks, R. J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3691-7 · Cited by 137
Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment
Dalmazi, G. D., Ippolito, S., Lupi, I., & Caturegli, P. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1701434 · Cited by 134
Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine
Li, J., Baird, M. A., Davis, M. A., Tai, W., Zweifel, L. S., Waldorf, K. M. A., Gale, M., Rajagopal, L., Pierce, R. H., & Gao, X. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0082 · Cited by 132
Are there multiple cells of origin of Merkel cell carcinoma?
Sunshine, J. C., Jahchan, N. S., Sage, J., & Choi, J. (2018) · Oncogene · doi:10.1038/s41388-017-0073-3 · Cited by 136
Self-citation
Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers
Guan, J., Lim, K. S., Mekhail, T. M., & Chang, C.-C. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0361-ra · Cited by 131
CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas
Guan, X., Zhang, C., Zhao, J., Sun, G., Song, Q., & Jia, W. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.012 · Cited by 128
Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma
Starrett, G. J., Thakuria, M., Chen, T., Marcelus, C., Cheng, J., Nomburg, J., Thorner, A. R., Slevin, M. K., Powers, W., Burns, R., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00727-4 · Cited by 127
Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade
Galanina, N., Goodman, A. M., Cohen, P. R., Frampton, G. M., & Kurzrock, R. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0121 · Cited by 126
Immunotherapy in advanced gastric cancer, is it the future?
Coutzac, C., Pernot, S., Chaput, N., & Zaanan, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.007 · Cited by 125
Merkel cell carcinoma: A review
Walsh, N. M. G., & Cerroni, L. (2020) · Journal of Cutaneous Pathology · doi:10.1111/cup.13910 · Cited by 124
A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort
Patel, S. P., Mayerson, E., Chae, Y. K., Strosberg, J., Wang, J., Konda, B., Hayward, J., McLeod, C. M., Chen, H. X., Sharon, E., et al. (2021) · Cancer · doi:10.1002/cncr.33591 · Cited by 124
Self-citation
Immune checkpoint inhibitors win the 2018 Nobel Prize
Huang, P., & Chang, J. W. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.09.002 · Cited by 130
Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models
Pierini, S., Gabbasov, R. T., Oliveira-Nunes, M. C., Qureshi, R., Worth, A. M., Huang, S., Nagar, K. K., Griffin, C., Lian, L., Yashiro–Ohtani, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55770-1 · Cited by 123
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review
Queirolo, P., & Spagnolo, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.002 · Cited by 121
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0541-9 · Cited by 122
Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
Cowey, C. L., Mahnke, L. A., Espirito, J. L., Helwig, C., Oksen, D., & Bharmal, M. F. (2017) · Future Oncology · doi:10.2217/fon-2017-0187 · Cited by 119
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 122
Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.007 · Cited by 118
Merkel cell carcinoma: An update and review
Tello, T. L., Coggshall, K., Yom, S. S., & Yu, S. S. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.004 · Cited by 117
Molecular Pathogenesis of Merkel Cell Carcinoma
DeCaprio, J. A. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032817 · Cited by 117
Merkel Cell Polyomavirus and Merkel Cell Carcinoma
Pietropaolo, V., Prezioso, C., & Moens, U. L. (2020) · Cancers · doi:10.3390/cancers12071774 · Cited by 120
Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy
Geels, S. N., Moshensky, A., Sousa, R. S., Murat, C., Bustos, M. A., Walker, B. L., Singh, R., Harbour, S. N., Gutierrez, G., Hwang, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.013 · Cited by 124
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Ng, H. H. M., Lee, R. Y., Goh, S., Tay, I. S. Y., Lim, X., Lee, B. T. K., Chew, V., Li, H., Tan, B., Lim, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000987 · Cited by 115
Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma
Chan, J. Y., Lim, J. Q., Yeong, J. P.-S., Ravi, V., Guan, P., Boot, A., Tay, T. K. Y., Selvarajan, S., Nasir, N. D. M., Loh, J. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139080 · Cited by 115
Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC
Becker, J. C., Stang, A., Hausen, A. Z., Fischer, N., DeCaprio, J. A., Tothill, R. W., Lyngaa, R., Hansen, U. K., Ritter, C., Nghiem, P., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2099-3 · Cited by 112
Self-citation
Mechanisms of Tumor Cell–Intrinsic Immune Evasion
Spranger, S., & Gajewski, T. F. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050606 · Cited by 113
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
Neilan, T. G., Rothenberg, M. L., Amiri‐Kordestani, L., Sullivan, R. J., Steingart, R. M., Gregory, W. W., Hariharan, S., Hammad, T. A., Lindenfeld, J. M., Murphy, M. J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0157 · Cited by 107
Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis
Petrelli, F., Ardito, R., Borgonovo, K., Lonati, V., Cabiddu, M., Ghilardi, M., & Barni, S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.129 · Cited by 107
Immunotherapy for Non-melanoma Skin Cancer
Shalhout, S. Z., Emerick, K. S., Kaufman, H. L., & Miller, D. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01120-z · Cited by 108
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Haddad, R. I., Seiwert, T. Y., Chow, L. Q. M., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B. A., Tahara, M., Keam, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003026 · Cited by 105
Merkel cell polyomavirus and Merkel cell carcinoma
DeCaprio, J. A. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0276 · Cited by 101
Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes
Colunga, A., Pulliam, T. H., & Nghiem, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0439 · Cited by 101
Self-citation
Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
Yeong, J. P.-S., Lim, J. C. T., Lee, B. T. K., Li, H., Ong, C. C. H., Thike, A. A., Yeap, W. H., Yang, Y. L., Lim, A. Y. H., Tay, T. K. Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0499-y · Cited by 104
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Zeidan, A. M., Knaus, H. A., Robinson, T. M., Towlerton, A. M. H., Warren, E. H., Zeidner, J. F., Blackford, A. L., Duffield, A. S., Rizzieri, D. A., Frattini, M. G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3763 · Cited by 98
Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy
Griffiths, J. I., Wallet, P., Pflieger, L. T., Stenehjem, D. D., Liu, X., Cosgrove, P. A., Leggett, N. A., McQuerry, J. A., Shrestha, G., Rossetti, M. M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918937117 · Cited by 100
Engineering chimeric antigen receptor-T cells for cancer treatment
Ye, B., Stary, C. M., Li, X., Gao, Q., Kang, C., & Xiong, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0814-0 · Cited by 95
Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy
Hendriks, L. E. L., Rouleau, É., & Besse, B. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.22 · Cited by 96
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma
Bhatia, S., Longino, N. V., Miller, N. J., Kulikauskas, R. M., Iyer, J. G., Ibrani, D., Blom, A., Byrd, D. R., Parvathaneni, U., Twitty, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0972 · Cited by 95
Self-citation
PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis
Wu, J., Hong, D., Zhang, X., Lu, X., & Miao, J. (2017) · Scientific Reports · doi:10.1038/srep44173 · Cited by 96
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 96
The application of nanotechnology in immune checkpoint blockade for cancer treatment
Deng, H., & Zhang, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.026 · Cited by 95
C-reactive protein as an early marker of immune-related adverse events
Abolhassani, A.-R., Schuler, G., Kirchberger, M. C., & Heinzerling, L. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03002-1 · Cited by 97
Immune checkpoint inhibitors to treat cutaneous malignancies
M.S, D. M. B., Do, M. H., Phillips, G. S., Postow, M. A., Akaike, T., Nghiem, P., & Lacouture, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.131 · Cited by 97
Self-citation
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 95
Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report
Paraghamian, S. E., Longoria, T. C., & Eskander, R. N. (2017) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-017-0038-9 · Cited by 94
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
Becker, J. C., Lorenz, E., Ugurel, S., Eigentler, T., Kiecker, F., Pföhler, C., Kellner, I., Meier, F. E., Kähler, K. C., Mohr, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19218 · Cited by 93
A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses
Zhai, W., Zhou, X., Wang, H., Li, W., Chen, G., Sui, X., Li, G., Qi, Y., & Gao, Y. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.005 · Cited by 93
Malignant pheochromocytoma–paraganglioma: pathogenesis, TNM staging, and current clinical trials
Román-Gonzaléz, A., & Jiménez, C. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000330 · Cited by 95
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor
Ngiow, S. F., Young, A., Blake, S. J., Hill, G. R., Yagita∥, H., Teng, M. W. L., Korman, A. J., & Smyth, M. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2141 · Cited by 93
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Mehnert, J. M., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D. E., Rubinstein, L., & Harris, L. N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3063 · Cited by 93
Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)
Sørbye, H., Baudin, É., Borbath, I., Caplin, M. E., Chen, J., Ćwikła, J. B., Frilling, A., Grossman, A. B., Kaltsas, G., Scarpa, A., et al. (2018) · Neuroendocrinology · doi:10.1159/000493318 · Cited by 92
Product review: Avelumab, an anti-PD-L1 antibody
Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1551671 · Cited by 91
Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival
Miller, N. J., Church, C. D., Dong, L., Crispin, D. A., Fitzgibbon, M., Lachance, K., Jing, L., Shinohara, M. M., Gavvovidis, I., Willimsky, G., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0210 · Cited by 92
Self-citation
Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance
Lewis, C. W., Qazi, J. J., Hippe, D. S., Lachance, K., Thomas, H. M. T., Cook, M. M., Juhlin, I., Singh, N., Thuesmunn, Z., Takagishi, S. R., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2781 · Cited by 91
Self-citation
Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness
Ning, J., Ye, Y., Bu, D., Zhao, G., Song, T., Liu, P., Yu, W., Wang, H., Li, H., Ren, X., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.016 · Cited by 91
Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses
Kidman, J., Principe, N., Watson, M. W., Lassmann, T., Holt, R. A., Nowak, A. K., Lesterhuis, W. J., Lake, R., & Chee, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587014 · Cited by 94
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 94
Management of primary skin cancer during a pandemic: Multidisciplinary recommendations
Baumann, B. C., MacArthur, K. M., Brewer, J. D., Mendenhall, W. M., Barker, C. A., Etzkorn, J. R., Jellinek, N. J., Scott, J. F., Gay, H. A., Baumann, J. C., et al. (2020) · Cancer · doi:10.1002/cncr.32969 · Cited by 87
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Wang, S., Xie, K., & Liu, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690112 · Cited by 90
Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia
Weber, M. M., & Fottner, C. (2018) · Oncology Research and Treatment · doi:10.1159/000488996 · Cited by 86
Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer
Bridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 86
Self-citation

Authors: Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, H. E., Lundgren, L., Margolin, K., Mitchell, A., Olencki, T., Pardoll, D. M., Reddy, S. A., Shantha, E. M., Sharfman, W. H., Sharon, E., Shemanski, L. R., Shinohara, M. M., Sunshine, J. C., Taube, J. M., Thompson, J. A., Townson, S. M., Yearley, J. H., Topalian, S. L., & Cheever, M. A.
Affiliations: Johns Hopkins University (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Mount Sinai Hospital (US)
ORCID: Nghiem, Paul T.
Bhatia, Shailender
Lipson, Evan J.
Kudchadkar, Ragini R.
Miller, Natalie J.
Berry, Sneha
Chartash, Elliot K.
Daud, Adil
Fling, Steven P.
Friedlander, Philip A.
Kluger, Harriet M.
Lundgren, Lisa
Margolin, Kim
Pardoll, Drew M.
Reddy, Sunil A.
Sharfman, William H.
Sharon, Elad
Shinohara, Michi M.
Sunshine, Joel C.
Taube, Janis M.
Thompson, John A.
Topalian, Suzanne L.
Cheever, Martin A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-06-30
Volume: 374
Issue: 26
Pages: 2542-2552
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1603702
PMC: PMC4927341
OpenAlex: W2339890238
Cited by: 1,258
References: 42
Citations by year: 2026: 40 · 2025: 68 · 2024: 76 · 2023: 86 · 2022: 104 · 2021: 141 · 2020: 166 · 2019: 172 · 2018: 187 · 2017: 174 · 2016: 40
FWCI: 103.02
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institutes of Health (5u01ca154967-06)
National Cancer Institute (U01-CA-154967, R01CA162522, 1U01CA154967, K24CA139052, UM1CA154967, R01CA142779, P30CA006973)
National Institute of General Medical Sciences (T32GM007266)
Topics: Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
Keywords: Merkel cell carcinoma, pembrolizumab, anti-PD-1 therapy, immune checkpoint inhibitors, Merkel cell polyomavirus, PD-L1 expression, first-line therapy, objective response rate, progression-free survival, cutaneous squamous cell carcinoma, immune-related adverse events, treatment-related adverse events, treatment duration, drug safety and efficacy
MeSH terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Staging, Recurrence, Skin Neoplasms, Carcinoma, Merkel Cell, Disease-Free Survival, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks